All In Biotech

Drug Trial Radar · NCT04233346

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

93

Actual

Start

Jul 9, 2020

Primary completion

Jul 22, 2022

Study completion Sep 8, 2026

Sponsor

Sponsor type
Industry
First posted
Jan 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia

Conditions

  • Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia

Interventions

  • Ponatinib 30mg ODDrug

    Ponatinib 30mg OD

  • Ponatinib 45mg ODDrug

    Ponatinib 45mg OD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MCyR(Major Cytogenetic Response) of CP-CML patientsTime frame: 12 months
  2. MaHR(Major Hematologic Response) of AP-CML, BP-CML and Ph+ ALL patients by 6 monthsTime frame: 6 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • 1st affiliated hospital, Peking University

    Beijing, China

  • Hematology Hospital, Chinese Academy of Medical Sciences

    Tianjin, China

  • Anhui Provincial Hospital

    Hefei, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Second hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Shenzhen Second People's Hospital

    Shenzhen, Shenzhen, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • The First Affiliated Hospital of Medical School of Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.